Evidence map›Paper›PMID 18357499›Full record

ArticleClinical rheumatology2008

Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.

H Bodur, S Ataman, L Akbulut, D Evcik, V Kavuncu, T Kaya, R Günaydin, B Kuran, N Kotevoğlu, A Bal and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Quality of life and related variables in patients with ankylosing spondylitis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2011
    Article
  11. Article
  12. Annual costs of rheumatoid arthritis in Turkey.Rheumatology international · 2010
    Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

H BodurPhysical Medicine and Rehabilitation (PMR) Department, Ankara Numune Training and Research Hospital, Mürsel Uluç Ankara, Turkey. haticebodur@gmail.com
S Ataman
L Akbulut
D Evcik
V Kavuncu
T Kaya
R Günaydin
B Kuran
N Kotevoğlu
A Bal
E Aydoğ
Z Altay
H Uğurlu
H Kocabaş
N Olmez
P Yazgan
S Gürsoy
E Madenci
S Ozel
S U Delialioğlu
Afyon Kocatepe University · TRAnkara Numune Eğitim ve Araştırma Hastanesi · TRDışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi · TRGaziantep University · TRIzmir University · TRMinistry of Health · TRSelçuk University · TRŞişli Etfal Eğitim ve Araştırma Hastanesi · TRAnkara University · TRHarran University · TRInonu University · TRIzmir Atatürk Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, progressive, systemic inflammatory rheumatic diseases that lead to serious disability. The objective of this study was to investigate the demographic and clinical characteristics of the patients with RA and AS who were treated in tertiary hospitals in Turkey and to analyze their current medical management. A total of 562 RA and 216 AS patients were evaluated. The mean age of RA patients was 52.1 +/- 12.6 years. The female to male ratio was 3.7:1. Of the RA patients, 72.2% had positive rheumatoid factor (RF), 62.9% had high C-reactive protein, and 75.2% had radiological erosion. The ratio of patients with Disease Activity Score (DAS) 28 >3.2 was 73.9% and of those with Health Assessment Questionnaire (HAQ) > or =1.5 was 20.9%. There was a statistically significant increase in RF positivity and HAQ scores in the group with higher DAS 28 score. Frequency of extraarticular manifestations was 22.4%. The ratio of the patients receiving disease modifying antirheumatic drugs (DMARD) was 93.1%, and 6.9% of the patients were using anti-tumor necrosis factor (TNF) blocking agents. In AS, the mean age of the patients was 38.1 +/- 10.6, and the female to male ratio was 1:2.5. The time elapsed between the first symptom and diagnosis was 4.3 years. The ratio of peripheral joint involvement was 29.4%. Major histocompatibility complex, class I, B 27 was investigated in 31.1% of patients and the rate of positivity was 91%. In 52.4% of the patients, Bath AS Disease Activity Index (BASDAI) was > or =4. The erythrocyte sedimentation rate, Bath AS Functional Index, and peripheral involvement were significantly higher in the group with BASDAI > or =4. Frequency of extraarticular involvement was 21.2% in AS patients. In the treatment schedule, 77.5% of AS patients were receiving sulphasalazine, 15% methotrexate, and 9.9% anti-TNF agents. Despite widespread use of DMARD, we observed high disease activity in more than half of the RA and AS patients. These results may be due to relatively insufficient usage of anti-TNF agents in our patients and therefore these results mostly reflect the traditional treatments. In conclusion, analysis of disease characteristics will inform us about the disease severity and activity in RA and AS patients and could help in selecting candidate patients for biological treatments.

Indexed as

Arthritis, RheumatoidSpondylitis, AnkylosingAntirheumatic AgentsC-Reactive ProteinFemaleHumansMaleMethotrexateMiddle AgedRadiographyRheumatoid FactorSulfasalazineTumor Necrosis Factor-alphaAntirheumatic AgentsC-Reactive ProteinMethotrexateRheumatoid FactorSulfasalazineTumor Necrosis Factor-alpha

Identifiers

PMID18357499
OpenAlexW2054388556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.